Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Sales Force More Focused, Not Smaller, After Vioxx Withdrawal

Dec 20 2004

• By The Pink Sheet

Related Content

Zocor Sales To Take $500 Mil. Hit In 2003 From Merck Inventory Program

Oct 27 2003

COX-2 Market Growth Could Be Stalled Until Release Of Long-Term Safety Data

Oct 04 2004

Merck/Schering’s Vytorin Clears FDA: Price Is 22% Discount To Lipitor

Aug 02 2004

Merck Fosamax Study Shows Benefit Vs. Actonel; Aventis/P&G Fault Endpoint

Oct 04 2004

Merck After Vioxx: No Merger, But No Big Near-Term Launches

Oct 04 2004

Merck To Increase Internal R&amp;D But Reduce Outside Deals In 2005

Dec 20 2004

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window